Key result
AMP-DNM cuts HbA1c ~47% in obese mice, restoring insulin sensitivity and reducing adipose inflammation.
Why the study?
Does AMP-DNM improve adipose tissue function and reduce inflammation in leptin-deficient obese mice?
Does AMP-DNM improve adipose tissue function and reduce inflammation in leptin-deficient obese mice?
Absolute Event Rate: 5.08% vs 9.64%
p-value: p=0.0006
Pharmacological lowering of glycosphingolipids with AMP-DNM improves adipocyte function and reduces adipose tissue inflammation in obese mice.
Hypothesis-generating for glycosphingolipid inhibition in obese mice; leaves open translation to human insulin resistance.
Adipose tissue is a critical mediator in obesity-induced insulin resistance. Previously we have demonstrated that pharmacological lowering of glycosphingolipids and subsequently GM3 by using the iminosugar AMP-DNM, strikingly improves glycemic control. Here we studied the effects of AMP-DNM on adipose tissue function and inflammation in detail to provide an explanation for the observed improved glucose homeostasis. Leptin-deficient obese (Lep(Ob)) mice were fed AMP-DNM and its effects on insulin signalling, adipogenesis and inflammation were monitored in fat tissue. We show that reduction of glycosphingolipid biosynthesis in adipose tissue of Lep(Ob) mice restores insulin signalling in isolated ex vivo insulin-stimulated adipocytes. We observed improved adipogenesis as the number of larger adipocytes was reduced and expression of genes like peroxisome proliferator-activated receptor (PPAR) gamma, insulin responsive glucose transporter (GLUT)-4 and adipsin increased. In addition, we found that adiponectin gene expression and protein were increased by AMP-DNM. As a consequence of this improved function of fat tissue we observed less inflammation, which was characterized by reduced numbers of adipose tissue macrophages (crown-like structures) and reduced levels of the macrophage chemo attractants monocyte-chemoattractant protein-1 (Mcp-1/Ccl2) and osteopontin (OPN). In conclusion, pharmacological lowering of glycosphingolipids by inhibition of glucosylceramide biosynthesis improves adipocyte function and as a consequence reduces inflammation in adipose tissue of obese animals.
No takes yet. Share an insight, caveat, or question.
Eijk et al. (2009) studied Obesity-induced insulin resistance (n=15). AMP-DNM vs. Untreated Lep Ob mice was evaluated on HbA1c (%) (p=0.0006). Treatment with the glucosylceramide synthesis inhibitor AMP-DNM in obese mice significantly reduced HbA1c from 9.64% to 5.08% and restored insulin sensitivity while reducing adipose tissue inflammation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: